Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Company Deals

Ipsen to Acquire Kartos Therapeutics for $450M Upfront, Adding Investigational MDM2 Inhibitor Navtemadlin to Myelofibrosis Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China

Fineline Cube Jan 7, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...

Company Drug

Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jan 7, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...

Policy / Regulatory

NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jan 7, 2025

The National Medical Products Administration (NMPA) has released the 88th batch of reference drugs for...

Company Drug

Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment

Fineline Cube Jan 7, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has indicated...

Company Drug

WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager

Fineline Cube Jan 7, 2025

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Drug

Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials

Fineline Cube Jan 7, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...

Company Deals

Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making

Fineline Cube Jan 7, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially submitted an initial public offering (IPO)...

Company Deals

Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization

Fineline Cube Jan 7, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...

Policy / Regulatory

CDE Announces 90th Batch of Reference Preparations for GQCE

Fineline Cube Jan 7, 2025

China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...

Company Deals Drug

Solasia Pharma Licenses Episil to GeneScience for Greater China Region

Fineline Cube Jan 7, 2025

Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...

Company Deals

Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines

Fineline Cube Jan 7, 2025

Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...

Company Drug

GSK’s Nucala Receives New Indication Approval in China for CRSwNP

Fineline Cube Jan 6, 2025

UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...

Policy / Regulatory

China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access

Fineline Cube Jan 6, 2025

The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...

Company Deals

Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau

Fineline Cube Jan 6, 2025

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...

Company Deals Medical Device

Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development

Fineline Cube Jan 6, 2025

China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...

Company Deals

Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round

Fineline Cube Jan 6, 2025

China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...

Company Drug

Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...

Company Deals

Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services

Fineline Cube Jan 6, 2025

China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...

Company Medical Device

Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA

Fineline Cube Jan 6, 2025

China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study

Fineline Cube Jan 6, 2025

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from...

Posts pagination

1 … 256 257 258 … 688

Recent updates

  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
  • AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
  • Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results
  • Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Company Medical Device

Roche Launches AXELIOS 1 Next-Generation Sequencing Platform Powered by Proprietary SBX Technology – Single-Molecule System Promises Same-Day Whole Genome Results

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.